Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19TNF plus standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma
2024-516357-46-00Phase 2Authorised
- Sponsor
- Philogen
- Start
- Mar 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of onfekafusp alfa and temozolomide in glioblastoma (GBM) (2 arms), sponsored by Philogen. Primary endpoints: Dose-limiting toxicity and Overall survival. Planned start Mar 2025; status: authorised.
02
Drugs
onfekafusp alfatemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-516357-46-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516357-46-00.